IL112010A - תכשירי רוקחות המכילים תולדות אוקסינדול מותמרות בעמדה 3 בעלי פעילות נגד היצרות כלי-דם - Google Patents

תכשירי רוקחות המכילים תולדות אוקסינדול מותמרות בעמדה 3 בעלי פעילות נגד היצרות כלי-דם

Info

Publication number: IL112010A
Authority: IL; Israel
Prior art keywords: oxindole; methylen; hydroxy; hydrogen; indolyl
Prior art date: 1993-12-22

Application number

IL11201094A

Other languages

English (en)

Other versions

IL112010A0 (en

Inventor

Buzzetti Franco

Longo Antonio

Brasca Maria Gabriella

Orzi Fabrizio

Crugnola Angelo

Ballinari Dario

Mariani Mariangela

Original Assignee

Erba Carlo Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-22

Filing date

1994-12-16

Publication date

1998-10-30

1994-12-16 Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa

1995-03-15 Publication of IL112010A0 publication Critical patent/IL112010A0/xx

1998-10-30 Publication of IL112010A publication Critical patent/IL112010A/he

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 9
230000001772 anti-angiogenic effect Effects 0.000 title claims description 3
125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 title 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims abstract description 46
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 44
239000001257 hydrogen Substances 0.000 claims abstract description 44
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 32
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract description 29
-1 cyano, carboxy Chemical group 0.000 claims abstract description 28
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims abstract description 26
150000002431 hydrogen Chemical group 0.000 claims abstract description 25
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims abstract description 22
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims abstract description 18
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims abstract description 18
150000003839 salts Chemical class 0.000 claims abstract description 18
229910052736 halogen Inorganic materials 0.000 claims abstract description 16
150000002367 halogens Chemical class 0.000 claims abstract description 16
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 15
125000001624 naphthyl group Chemical group 0.000 claims abstract description 14
239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 13
125000001424 substituent group Chemical group 0.000 claims abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
125000002619 bicyclic group Chemical group 0.000 claims abstract description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
125000001041 indolyl group Chemical group 0.000 claims abstract description 9
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims abstract description 7
125000004423 acyloxy group Chemical group 0.000 claims abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 5
125000003118 aryl group Chemical group 0.000 claims abstract description 4
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 4
125000001589 carboacyl group Chemical group 0.000 claims abstract description 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 86
125000000217 alkyl group Chemical group 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 10
239000002246 antineoplastic agent Substances 0.000 claims description 9
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 6
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
238000011319 anticancer therapy Methods 0.000 claims description 2
230000014399 negative regulation of angiogenesis Effects 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
229920002261 Corn starch Polymers 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
102000007399 Nuclear hormone receptor Human genes 0.000 description 5
108020005497 Nuclear hormone receptor Proteins 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
238000000034 method Methods 0.000 description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000003711 chorioallantoic membrane Anatomy 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
235000013681 dietary sucrose Nutrition 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229940045799 anthracyclines and related substance Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960001904 epirubicin Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960000908 idarubicin Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960002900 methylcellulose Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
YCEADMGZFFVDRF-UHFFFAOYSA-N 2-[(2-oxo-1h-indol-3-ylidene)methyl]-1h-quinolin-4-one Chemical compound C1=CC=C2C(O)=CC(C=C3C4=CC=CC=C4NC3=O)=NC2=C1 YCEADMGZFFVDRF-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
NBUVXZLQSFVQLE-UHFFFAOYSA-N 3-(naphthalen-1-ylmethylidene)-1h-indol-2-one Chemical compound C1=CC=C2C(C=C3C4=CC=CC=C4NC3=O)=CC=CC2=C1 NBUVXZLQSFVQLE-UHFFFAOYSA-N 0.000 description 1
FDYKNSMXGMFDMO-UHFFFAOYSA-N 3-(quinolin-2-ylmethylidene)-1h-indol-2-one Chemical compound C1=CC=CC2=NC(C=C3C4=CC=CC=C4NC3=O)=CC=C21 FDYKNSMXGMFDMO-UHFFFAOYSA-N 0.000 description 1
YSNDWAQWWQVUEA-UHFFFAOYSA-N 3-(quinolin-3-ylmethylidene)-1h-indol-2-one Chemical compound C1=CC=CC2=CC(C=C3C4=CC=CC=C4NC3=O)=CN=C21 YSNDWAQWWQVUEA-UHFFFAOYSA-N 0.000 description 1
UBEIHUVCYODJRE-UHFFFAOYSA-N 3-(quinolin-4-ylmethylidene)-1h-indol-2-one Chemical compound C1=CC=C2C(C=C3C4=CC=CC=C4NC3=O)=CC=NC2=C1 UBEIHUVCYODJRE-UHFFFAOYSA-N 0.000 description 1
UYHZBOIZTNEWIS-UHFFFAOYSA-N 3-(quinolin-5-ylmethylidene)-1h-indol-2-one Chemical compound C1=CC=C2C(C=C3C4=CC=CC=C4NC3=O)=CC=CC2=N1 UYHZBOIZTNEWIS-UHFFFAOYSA-N 0.000 description 1
NRUSUSGSMWNSBP-UHFFFAOYSA-N 3-(quinolin-6-ylmethylidene)-1h-indol-2-one Chemical compound N1=CC=CC2=CC(C=C3C4=CC=CC=C4NC3=O)=CC=C21 NRUSUSGSMWNSBP-UHFFFAOYSA-N 0.000 description 1
VTPAWIKIHLGCQL-UHFFFAOYSA-N 3-[(5-hydroxyquinolin-6-yl)methylidene]-1H-indol-2-one Chemical compound C1=CC2=NC=CC=C2C(O)=C1C=C1C2=CC=CC=C2NC1=O VTPAWIKIHLGCQL-UHFFFAOYSA-N 0.000 description 1
MTKXBUKOYWHHNH-UHFFFAOYSA-N 3-[(6-hydroxyquinolin-5-yl)methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CC1=C2C=CC=NC2=CC=C1O MTKXBUKOYWHHNH-UHFFFAOYSA-N 0.000 description 1
GFWVFGAANXPHBH-UHFFFAOYSA-N 3-[(8-hydroxyquinolin-6-yl)methylidene]-1h-indol-2-one Chemical compound C1=CN=C2C(O)=CC(C=C3C4=CC=CC=C4NC3=O)=CC2=C1 GFWVFGAANXPHBH-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
AXDGBHAKCVDUFC-UHFFFAOYSA-N C1=CC=NC2=CC(O)=CC(C=C3C4=CC=CC=C4NC3=O)=C21 Chemical compound C1=CC=NC2=CC(O)=CC(C=C3C4=CC=CC=C4NC3=O)=C21 AXDGBHAKCVDUFC-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241001055367 Dario Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
MXUMMLAFFBFLRW-UHFFFAOYSA-N O=C1NC2=CC=CC=C2C1=CC1=CC2=CC=CN=C2C=C1O Chemical compound O=C1NC2=CC=CC=C2C1=CC1=CC2=CC=CN=C2C=C1O MXUMMLAFFBFLRW-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000005623 oxindoles Chemical class 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
150000003870 salicylic acids Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL11201094A 1993-12-22 1994-12-16 תכשירי רוקחות המכילים תולדות אוקסינדול מותמרות בעמדה 3 בעלי פעילות נגד היצרות כלי-דם IL112010A (he)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939326136A GB9326136D0 (en)	1993-12-22	1993-12-22	Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

Publications (2)

Publication Number	Publication Date
IL112010A0 IL112010A0 (en)	1995-03-15
IL112010A true IL112010A (he)	1998-10-30

Family

ID=10746990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11201094A IL112010A (he)	1993-12-22	1994-12-16	תכשירי רוקחות המכילים תולדות אוקסינדול מותמרות בעמדה 3 בעלי פעילות נגד היצרות כלי-דם

Country Status (17)

Country	Link
US (1)	US5576330A (he)
EP (1)	EP0684820B1 (he)
JP (1)	JPH08507089A (he)
KR (1)	KR960700707A (he)
AT (1)	ATE204168T1 (he)
AU (1)	AU676958B2 (he)
CA (1)	CA2155098A1 (he)
DE (1)	DE69427962T2 (he)
ES (1)	ES2162871T3 (he)
GB (1)	GB9326136D0 (he)
HU (1)	HUT73176A (he)
IL (1)	IL112010A (he)
NO (1)	NO953146D0 (he)
PL (1)	PL310379A1 (he)
TW (1)	TW273510B (he)
WO (1)	WO1995017181A1 (he)
ZA (1)	ZA9410204B (he)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9501567D0 (en) *	1995-01-26	1995-03-15	Pharmacia Spa	Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US6906093B2 (en)	1995-06-07	2005-06-14	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6147106A (en)	1997-08-20	2000-11-14	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9610964D0 (en) *	1996-05-24	1996-07-31	Pharmacia & Upjohn Spa	Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) *	1996-06-06	1996-08-07	Pharmacia Spa	Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9613021D0 (en) *	1996-06-21	1996-08-28	Pharmacia Spa	Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
WO1998024432A2 (en) *	1996-12-05	1998-06-11	Sugen, Inc.	Use of indolinone compounds as modulators of protein kinases
WO1999009982A1 (en)	1997-08-25	1999-03-04	Harold Brem	Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
US6531502B1 (en)	1998-01-21	2003-03-11	Sugen, Inc.	3-Methylidenyl-2-indolinone modulators of protein kinase
US6569868B2 (en)	1998-04-16	2003-05-27	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
CA2333147C (en)	1998-07-13	2012-02-07	Board Of Regents, The University Of Texas System	Cancer treatment methods using antibodies to aminophospholipids
SI1107795T1 (en)	1998-09-04	2003-06-30	The Regents Of The University Of Michigan	Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
AU5991699A (en)	1998-09-21	2000-04-10	Biochem Pharma Inc.	Quinolizinones as integrin inhibitors
CN1136217C (zh)	1998-12-17	2004-01-28	霍夫曼-拉罗奇有限公司	作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
KR20010108024A (ko)	1998-12-17	2001-12-07	프리돌린 클라우스너, 롤란드 비. 보레르	단백질 키나제 억제제로서의 4,5-피라진옥신돌
US6153634A (en) *	1998-12-17	2000-11-28	Hoffmann-La Roche Inc.	4,5-azolo-oxindoles
BR9916327A (pt)	1998-12-17	2001-09-18	Hoffmann La Roche	Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6509334B1 (en) *	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en)	1999-05-04	2002-05-21	American Home Products Corporation	Indoline derivatives
US6355648B1 (en) *	1999-05-04	2002-03-12	American Home Products Corporation	Thio-oxindole derivatives
US6673843B2 (en) *	1999-06-30	2004-01-06	Emory University	Curcumin and curcuminoid inhibition of angiogenesis
US6313310B1 (en)	1999-12-15	2001-11-06	Hoffmann-La Roche Inc.	4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
JP3663382B2 (ja)	2000-02-15	2005-06-22	スージェン・インコーポレーテッド	ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
MY128450A (en)	2000-05-24	2007-02-28	Upjohn Co	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AU2001258628A1 (en) *	2000-05-31	2001-12-11	Astrazeneca Ab	Indole derivatives with vascular damaging activity
JP2003535847A (ja)	2000-06-02	2003-12-02	スージェン・インコーポレーテッド	蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
AU9598601A (en)	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
AR042586A1 (es)	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6599902B2 (en)	2001-05-30	2003-07-29	Sugen, Inc.	5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
EP1572078A4 (en) *	2002-03-08	2006-08-09	Univ Emory	NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
KR20120068769A (ko)	2002-07-15	2012-06-27	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
ATE508747T1 (de)	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
US7683172B2 (en)	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
KR101395370B1 (ko)	2004-01-22	2014-05-14	유니버시티 오브 마이애미	국소용 코-엔자임 큐10 제형 및 그의 사용 방법
ATE428421T1 (de)	2004-09-17	2009-05-15	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
CN104706637A (zh)	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
CA2676796C (en)	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
CA2705152C (en)	2007-11-09	2016-10-11	Peregrine Pharmaceuticals, Inc.	Anti-vegf antibody compositions and methods
US8952035B2 (en)	2007-11-09	2015-02-10	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2323679A4 (en)	2008-07-25	2012-08-22	Univ Colorado	CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
MY162940A (en)	2009-08-19	2017-07-31	Eisai R&D Man Co Ltd	Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
CN102115469A (zh) *	2011-03-21	2011-07-06	浙江大学	吲哚啉-2-酮类衍生物的制备和用途
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR20150098605A (ko)	2012-12-21	2015-08-28	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en)	2013-05-14	2020-05-29	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP2837626A1 (en) *	2013-08-16	2015-02-18	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Indolinone derivatives as GRK5 modulators
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
US12220398B2 (en)	2015-08-20	2025-02-11	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
EP3576726A1 (en)	2017-02-06	2019-12-11	Massachusetts Institute Of Technology	Methods and products related to glutaminase inhibitors
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9000950D0 (en) *	1990-01-16	1990-03-14	Erba Carlo Spa	New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) *	1990-01-16	1990-03-14	Erba Carlo Spa	Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) *	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
FI935279L (fi) *	1991-05-29	1993-11-26	Pfizer	Tricykliska polyhydroxyltyrosinkinasininhibitorer
GB9115160D0 (en) *	1991-07-12	1991-08-28	Erba Carlo Spa	Methylen-oxindole derivatives and process for their preparation
GB9127376D0 (en) *	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
WO1994003427A1 (en) *	1992-08-06	1994-02-17	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation

1993
- 1993-12-22 GB GB939326136A patent/GB9326136D0/en active Pending
1994
- 1994-11-08 CA CA002155098A patent/CA2155098A1/en not_active Abandoned
- 1994-11-08 ES ES94931583T patent/ES2162871T3/es not_active Expired - Lifetime
- 1994-11-08 KR KR1019950703524A patent/KR960700707A/ko not_active Withdrawn
- 1994-11-08 HU HU9502761A patent/HUT73176A/hu unknown
- 1994-11-08 PL PL94310379A patent/PL310379A1/xx unknown
- 1994-11-08 WO PCT/EP1994/003664 patent/WO1995017181A1/en not_active Ceased
- 1994-11-08 AU AU80612/94A patent/AU676958B2/en not_active Ceased
- 1994-11-08 JP JP7517121A patent/JPH08507089A/ja active Pending
- 1994-11-08 AT AT94931583T patent/ATE204168T1/de not_active IP Right Cessation
- 1994-11-08 EP EP94931583A patent/EP0684820B1/en not_active Expired - Lifetime
- 1994-11-08 DE DE69427962T patent/DE69427962T2/de not_active Expired - Fee Related
- 1994-11-15 TW TW083110552A patent/TW273510B/zh active
- 1994-12-12 US US08/354,215 patent/US5576330A/en not_active Expired - Fee Related
- 1994-12-12 ZA ZA9410204A patent/ZA9410204B/xx unknown
- 1994-12-16 IL IL11201094A patent/IL112010A/he not_active IP Right Cessation
1995
- 1995-08-10 NO NO953146A patent/NO953146D0/no unknown

Also Published As

Publication number	Publication date
KR960700707A (ko)	1996-02-24
GB9326136D0 (en)	1994-02-23
NO953146L (no)	1995-08-10
ZA9410204B (en)	1995-11-10
AU8061294A (en)	1995-07-10
US5576330A (en)	1996-11-19
ATE204168T1 (de)	2001-09-15
NO953146D0 (no)	1995-08-10
DE69427962D1 (de)	2001-09-20
CA2155098A1 (en)	1995-06-29
EP0684820A1 (en)	1995-12-06
WO1995017181A1 (en)	1995-06-29
HU9502761D0 (en)	1995-11-28
JPH08507089A (ja)	1996-07-30
ES2162871T3 (es)	2002-01-16
PL310379A1 (en)	1995-12-11
IL112010A0 (en)	1995-03-15
HUT73176A (en)	1996-06-28
EP0684820B1 (en)	2001-08-16
AU676958B2 (en)	1997-03-27
DE69427962T2 (de)	2002-04-04
TW273510B (he)	1996-04-01

Legal Events

Date	Code	Title	Description
1999-03-12	FF	Patent granted
2001-08-26	MM9K	Patent not in force due to non-payment of renewal fees
2011-02-28	HK	Corrigendum	Free format text: ADD COUNTRY OF APPLICANT: USA; CORRECT INTERNATIONAL PUBLICATION NO.: WO/2003/009465; CORRECT PRIORITY NUMBER: 00110355.5

Publication	Publication Date	Title
US5576330A (en)	1996-11-19	Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5948808A (en)	1999-09-07	Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
CA2924318C (en)	2019-12-24	Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
US8685934B2 (en)	2014-04-01	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
RU2072989C1 (ru)	1997-02-10	Производные метиленоксиндола, способ их получения и фармацевтическая композиция
US5498405A (en)	1996-03-12	Indole alkaloids useful as UV protective and anti-inflammatory agents
EP1218004B1 (en)	2009-04-08	5-methyl indirubin for use in the treatment of human solid tumors
AU777377B2 (en)	2004-10-14	Dibenzo(a,g)quinolizinium derivatives and the salts thereof
WO1989007441A1 (en)	1989-08-24	6-amino-1,2-benzopyrone antitumorigenic agents and method
CN106749478B (zh)	2017-11-07	pH敏感的1,4‑二取代酞菁锌配合物及其制备方法和在医药上的应用
EP0787494B1 (en)	2004-06-09	Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori
CA1307739C (en)	1992-09-22	Anti-inflammatory compositions
AU705751B2 (en)	1999-06-03	An agent for inhibiting carcinogenesis
CA2213693C (en)	2008-04-15	Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
De Oliveira et al.	1978	Effects of quinone derivatives on an experimental tumor
CA2518748A1 (en)	2004-09-23	Antimicrobial agents and anticancer agents
CN116802175B (zh)	2025-09-30	谷氨酰胺类似物
JPH0374329A (ja)	1991-03-28	胃炎治療剤
WO1990015811A1 (fr)	1990-12-27	Spicamycine x et son utilisation
WEARLEY et al.	1976	1.1 Name, Formula, Molecular Weight
EP1075484A1 (en)	2001-02-14	Novel anthracycline derivatives and their preparation
JPH04368329A (ja)	1992-12-21	チアミンコバルトクロロフィリン錯化合物含有製剤
MXPA01009025A (es)	2002-10-23	L-arabino-disacaridos de antraciclinas, proceso para su preparacion, y composiciones farmaceuticas que los contienen..
IE20000248A1 (en)	2000-11-29	An adduct containing Clarithromycin and Ranitidine